Med-X, which manufactures natural pesticides and other green products under various brands, increased the number of shares to be registered in connection with its direct listing on Thursday. The shares of common stock listed will be sold by existing shareholders; Med-X will not raise new capital in its listing.
The Canoga Park, CA-based company now plans to register 16.2 million shares for resale by existing shareholders in its direct listing. The company had previously filed to register 13.2 million shares. Med-X raised $1.2 million between July and October 2026 by selling 0.2 million shares at $6.00 per share (adjusted for a 1-for-2 reverse split to take effect before listing); at that price, the company would command a fully diluted market value of $97 million (+23% versus previous terms).
Med-X develops and markets natural "green" products under its Nature-Cide, Thermal-Aid and Malibu Brands divisions. Nature-Cide makes minimum risk botanical pesticides and repellents for professional pest control, hospitality, agriculture and other uses, while Thermal-Aid makes natural heating and cooling pain relief products. Both are sold through national distributors and ecommerce platforms.
Med-X was founded in 2014 and booked $2 million in revenue for the 12 months ended June 30, 2026. It plans to list on the Nasdaq under the symbol MXRX. Med-X filed confidentially on January 28, 2026. As a direct listing without a firm commitment offering, there are no underwriters on the deal; instead, Maxim Group will serve as financial advisor.
